Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

• Status: Completed
• Trial end date: 2017-03-02
• Target enrollment: 0
• Participant gender: All

Summary

This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal choroidal vasculopathy (PCV). The results of this study provided long-term safety and efficacy data used to generate further guidance on the management of patients with PCV.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Ranibizumab; Verteporfin

Criteria

Inclusion Criteria:

• Confirmed diagnosis of symptomatic macular PCV in the study eye

• A qualifying vision score at study entry

• A qualifying lesion size in the study eye at study entry

Exclusion Criteria:

• Active inflammation or infection in the study eye

• Uncontrolled intraocular pressure in the stuy eye

• Ocular condition in the study eye which may impact vision and confound study outcomes

• Prior treatment of the study eye with anti-VEGF therapy, verteporfin PDT, other laser and surgical interventions, intraocular corticosteroids